TY - JOUR
T1 - M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
AU - Hensler, Michal
AU - Kasikova, Lenka
AU - Fiser, Karel
AU - Rakova, Jana
AU - Skapa, Petr
AU - Laco, Jan
AU - Lanickova, Tereza
AU - Pecen, Ladislav
AU - Truxova, Iva
AU - Vosahlikova, Sarka
AU - Moserova, Irena
AU - Praznovec, Ivan
AU - Drochytek, Vit
AU - Rehackova, Martina
AU - Brtnicky, Tomas
AU - Rob, Lukas
AU - Benes, Vladimir
AU - Pistolic, Jelena
AU - Sojka, Ludek
AU - Ryska, Ales
AU - Sautes-Fridman, Catherine
AU - Fridman, Wolf Herve
AU - Galluzzi, Lorenzo
AU - Spisek, Radek
AU - Fucikova, Jitka
N1 - Publisher Copyright:
©
PY - 2020/8/20
Y1 - 2020/8/20
N2 - Background The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of the immunological configuration of HGSC metastases. Methods RNA sequencing was employed on 24 paired primary tumor microenvironment (P-TME) and metastatic tumor microenvironment (M-TME) chemotherapy-naive HGSC samples. Immunohistochemistry was used to evaluate infiltration by CD8 + T cells, CD20 + B cells, DC-LAMP + (lysosomal-associated membrane protein 3) dendritic cells (DCs), NKp46 + (natural killer) cells and CD68 + CD163 + M2-like tumor-associated macrophages (TAMs), abundance of PD-1 + (programmed cell death 1), LAG-3 + (lymphocyte-activating gene 3) cells, and PD-L1 (programmed death ligand 1) expression in 80 samples. Flow cytometry was used for functional assessments on freshly resected HGSC samples. Results 1468 genes were differentially expressed in the P-TME versus M-TME of HGSCs, the latter displaying signatures of extracellular matrix remodeling and immune infiltration. M-TME infiltration by immune effector cells had little impact on patient survival. Accordingly, M-TME-infiltrating T cells were functionally impaired, but not upon checkpoint activation. Conversely, cytokine signaling in favor of M2-like TAMs activity appeared to underlie inhibited immunity in the M-TME and poor disease outcome. Conclusions Immunosuppressive M2-like TAM infiltrating metastatic sites limit clinically relevant immune responses against HGSCs.
AB - Background The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of the immunological configuration of HGSC metastases. Methods RNA sequencing was employed on 24 paired primary tumor microenvironment (P-TME) and metastatic tumor microenvironment (M-TME) chemotherapy-naive HGSC samples. Immunohistochemistry was used to evaluate infiltration by CD8 + T cells, CD20 + B cells, DC-LAMP + (lysosomal-associated membrane protein 3) dendritic cells (DCs), NKp46 + (natural killer) cells and CD68 + CD163 + M2-like tumor-associated macrophages (TAMs), abundance of PD-1 + (programmed cell death 1), LAG-3 + (lymphocyte-activating gene 3) cells, and PD-L1 (programmed death ligand 1) expression in 80 samples. Flow cytometry was used for functional assessments on freshly resected HGSC samples. Results 1468 genes were differentially expressed in the P-TME versus M-TME of HGSCs, the latter displaying signatures of extracellular matrix remodeling and immune infiltration. M-TME infiltration by immune effector cells had little impact on patient survival. Accordingly, M-TME-infiltrating T cells were functionally impaired, but not upon checkpoint activation. Conversely, cytokine signaling in favor of M2-like TAMs activity appeared to underlie inhibited immunity in the M-TME and poor disease outcome. Conclusions Immunosuppressive M2-like TAM infiltrating metastatic sites limit clinically relevant immune responses against HGSCs.
KW - macrophages
KW - tumor biomarkers
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85089769957&partnerID=8YFLogxK
U2 - 10.1136/jitc-2020-000979
DO - 10.1136/jitc-2020-000979
M3 - Article
C2 - 32819974
AN - SCOPUS:85089769957
SN - 2051-1426
VL - 8
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 2
M1 - e000979
ER -